Myriad Genetics (MYGN) Expected to Announce Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) is expected to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect Myriad Genetics to post earnings of ($0.02) per share and revenue of $202.30 million for the quarter. Myriad Genetics has set its FY 2025 guidance at -0.020-0.020 EPS.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Myriad Genetics had a negative return on equity of 4.95% and a negative net margin of 12.20%. The firm had revenue of $195.90 million during the quarter, compared to the consensus estimate of $200.37 million. During the same period in the prior year, the business earned ($0.01) EPS. The firm’s revenue was down 33.6% on a year-over-year basis. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Trading Up 1.8%

Shares of MYGN stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.71 and a current ratio of 1.90. Myriad Genetics has a 1 year low of $3.76 and a 1 year high of $29.30. The stock has a fifty day moving average of $4.89 and a two-hundred day moving average of $7.90. The firm has a market capitalization of $360.42 million, a PE ratio of -3.49 and a beta of 1.89.

Institutional Trading of Myriad Genetics

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its stake in Myriad Genetics by 1,076.9% during the 1st quarter. Jane Street Group LLC now owns 213,826 shares of the company’s stock valued at $1,897,000 after purchasing an additional 195,658 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Myriad Genetics by 4.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,256 shares of the company’s stock worth $2,654,000 after buying an additional 14,027 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Myriad Genetics by 278.9% in the 1st quarter. AQR Capital Management LLC now owns 433,392 shares of the company’s stock worth $3,844,000 after buying an additional 319,007 shares in the last quarter. Royal Bank of Canada increased its holdings in Myriad Genetics by 82.4% during the 1st quarter. Royal Bank of Canada now owns 33,326 shares of the company’s stock valued at $296,000 after purchasing an additional 15,057 shares in the last quarter. Finally, Baird Financial Group Inc. acquired a new stake in Myriad Genetics during the 1st quarter valued at $105,000. Institutional investors own 99.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MYGN. Raymond James Financial reiterated an “outperform” rating and set a $10.00 price target (down previously from $19.00) on shares of Myriad Genetics in a research report on Wednesday, May 7th. Craig Hallum set a $18.00 target price on Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, May 7th. The Goldman Sachs Group dropped their price target on Myriad Genetics from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company lowered Myriad Genetics from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $22.00 to $6.00 in a research report on Wednesday, May 7th. Finally, Piper Sandler dropped their target price on Myriad Genetics from $12.50 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, May 15th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $14.38.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.